Robert Doebele and Avanish Vellanki (Rain)
New targeted therapy approaches win Rain Therapeutics $63M — designed to beat a quick path to approval
Rain Therapeutics is on a tear.
When the biotech got started in the San Francisco Bay Area, it was singularly focused on tarloxotinib, a small molecule inhibitor named for its design to target low oxygen levels in the tumor and thereby sparing healthy tissues. More than two years later, Rain has tripled its pipeline within days, first licensing a research program from Drexel University, then more recently nabbing a Phase II-ready drug from Daiichi Sankyo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
